Neurogen down on failed Phase IIa

NRGN was down $1.76 (19%) to $7.55 on Wednesday after its NGD 2000-1 missed the primary endpoint in a Phase IIa trial for mild to moderate rheumatoid arthritis (RA). The double-blind, placebo-controll...